Tango Therapeutics, Inc.
7.83+0.04 (+0.51%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · TNGX · USD
Key Stats
Market Cap
1.04BP/E (TTM)
-Basic EPS (TTM)
-1.32Dividend Yield
0%Recent Filings
8-K
Vopimetostat trial yields strong data
Tango Therapeutics reported $152.8 million in cash, cash equivalents, and marketable securities as of September 30, 2025, bolstering its runway for clinical advancement. The Phase 1/2 trial of vopimetostat, an oral PRMT5 inhibitor, showed robust activity in MTAP-deleted solid tumors, with 27% overall response rate and 6.4 months median progression-free survival across 154 patients at active doses. In second-line pancreatic cancer, it delivered 25% ORR and 7.2 months mPFS, outpacing historical chemotherapy benchmarks. A pivotal trial starts in 2026; combination studies with RAS inhibitors advance in first-line settings.
10-Q
Q2 FY2025 results
Tango Therapeutics posted Q2 revenue of $3.2 million from its Gilead collaboration, down from $19.9 million a year earlier due to a one-time $12.0 million license fee last year and lower research activity. Operating expenses fell to $44.1 million from $49.4 million, mainly from discontinuing TNG908 and TNG348 programs, though TNG462 and new efforts like TNG456 advanced. This narrowed the operating loss to $41.0 million from $29.6 million, with net loss at $38.9 million or $0.35 per share on 110.5 million diluted shares—wider than last year's $25.6 million or $0.24 per share, driven by interest and other income dropping to $2.1 million from $4.1 million. Cash and equivalents stood at $180.8 million, funding operations into Q1 2027, while the Gilead research term ended early on August 4, 2025, unlocking $53.8 million in deferred revenue for Q3 recognition. No debt burdens or M&A events noted. Clinical trials remain vulnerable to enrollment delays.
8-K
Pipeline advances, revenue boost
Tango Therapeutics advanced its pipeline in Q2 2025, dosing the first patient in a TNG462 combination trial with Revolution Medicines' RAS(ON) inhibitors for MTAP-deleted cancers, while TNG456 entered Phase 1/2 for glioblastoma. The company truncated its Gilead collaboration research term without penalty, recognizing $53.8 million in deferred revenue this quarter. Cash stands at $180.8 million, funding operations into Q1 2027. Data updates for TNG462 and TNG260 loom in H2.
8-K
Stockholders approve share increase
Tango Therapeutics' stockholders approved key measures at the June 5, 2025 annual meeting, including Lesley Ann Calhoun's election to the board and ratification of PricewaterhouseCoopers as auditors for 2025. They also greenlit doubling authorized common shares to 400 million, effective immediately, while endorsing annual say-on-pay votes. This boosts flexibility for future equity issuances. No other matters arose.
CERO
CERo Therapeutics Holdings, Inc
1.79-0.09
MBIO
Mustang Bio, Inc.
1.47-0.03
MRKR
Marker Therapeutics, Inc.
0.97-0.04
PRLD
Prelude Therapeutics Incorporat
1.58+0.04
RNAZ
TransCode Therapeutics, Inc.
11.93-0.57
RNXT
RenovoRx, Inc.
1.05-0.08
RPTX
Repare Therapeutics Inc.
1.78-0.01
SLXN
Silexion Therapeutics Corp
3.44+0.01
SMMT
Summit Therapeutics Inc.
18.66-0.57
TCRX
TScan Therapeutics, Inc.
1.92-0.21